APF530 (Granisetron Injection Extended-Release) in a Three-Drug Regimen for Delayed CINV in Highly Emetogenic Chemotherapy

201622 citationsJournal Articlebronze Open Access

Authors

APF530 versus the standard three-drug regimen provided superior control of delayed-phase CINV following HEC. ClinicalTrials.gov : NCT02106494.

Good health and well-being

Published in: Future Oncology

Volume 12, Issue 12, pp. 1469-1481

Field-Weighted Citation Impact: 5.50